BOIRF (Boiron) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOIRF Boiron SA BOIRF
66 GF Score
Price $31.50
GF Value $33.52
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Boiron Short-term investments?

Short-term investments only applies to insurance companies.

BOIRF
66GF Score
Boiron SA BOIRF
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Boiron (BOIRF) Overvalued in 2026?

Based on GuruFocus' analysis, Boiron stock appears to be undervalued. The current stock price of $31.50 is trading 6% below its estimated GF Value™ of $33.52. GuruFocus considers Boiron to be Fairly Valued.

Key valuation signals for BOIRF:

  • Short-term investments:
  • GF Value™: $33.52 vs. price of $31.50 (6% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boiron Business Description

Address 2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
66GF Score

Get the complete analysis for BOIRF

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.50
Price
$33.52
GF Value